Clinical translation of antibody-radionuclide conjugates in oncology: a scoping review of first-in-human trials, dose escalation, imaging-guided selection, and dosimetry-guided dosing
Research Connections · 18.11.2026
DOI: 10.1093/rescon/vmag220 ↗Kurz gefasst
Scoping Review in der Zeitschrift Research Connections, online erschienen am 18.11.2026. Verfasst von Emmanuel O Oisakede und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antibody-radionuclide conjugates (ARCs) combine antibody-mediated tumour targeting with therapeutic radiation, but their clinical development remains heterogeneous. The therapeutic applications of these radionuclides now extend to several haematological malignancies and selected solid tumours, with ongoing clinical trials evaluating their potential in other major cancer types. This review mapped early clinical translation, focusing on trial design, dose escalation, imaging-guided selection, dosimetry, efficacy, safety and resistance. MEDLINE/PubMed, Embase, Scopus, Cochrane CENTRAL, Web of Science, ClinicalTrials.gov and relevant conference proceedings were searched for publications from 1 January 2011 to 20 August 2026. Eligible studies evaluated therapeutic antibody-based radionuclide conjugates in solid or haematological malignancies. Data were charted and synthesised narratively in accordance with PRISMA-ScR. Forty-two publications representing 39 clinical programmes were included. Thirty-six (85.7%) concerned haematological malignancies and six (14.3%) solid tumours. Thirty-one (73.8%) focused on B-cell non-Hodgkin lymphoma. CD20 was the predominant target (27/42, 64.3%). Yttrium-90 (22/42, 52.4%) and iodine-131 (13/42, 31.0%) dominated, whereas lutetium-177 appeared in three publications and thorium-227, lead-212, rhenium-188 and actinium-225 in one each. In the actinium-225–J591 prostate cancer trial, one of 22 patients experienced dose-limiting toxicity during escalation. Dose escalation was usually based on administered activity, body weight or organ-dose ceilings. Imaging was widely used for biodistribution and dosimetry but less consistently for eligibility or treatment adaptation. Dosimetry methods, imaging schedules and response criteria varied substantially. Haematological toxicity, particularly thrombocytopenia and neutropenia, was the principal treatment-limiting toxicity. Lesion-level analyses demonstrated heterogeneous uptake, absorbed dose and response, while biological resistance mechanisms were rarely investigated prospectively. In the mapped evidence, ARC activity was clearest in lymphoma, while dosing, imaging and safety reporting remained inconsistent. Prospective studies are needed to establish whether imaging-guided selection or tumour-dose-based prescriptions improve outcomes, alongside longer safety follow-up and evaluation of service delivery.
Zitieren
APA
Oisakede, E. O., Adegbenro, A. T., Amhakhian, O. A., Ukponahunsi, E., & Olawade, D. B. (2026). Clinical translation of antibody-radionuclide conjugates in oncology: a scoping review of first-in-human trials, dose escalation, imaging-guided selection, and dosimetry-guided dosing. Research Connections. https://doi.org/10.1093/rescon/vmag220
Vancouver
Oisakede EO, Adegbenro AT, Amhakhian OA, Ukponahunsi E, Olawade DB. Clinical translation of antibody-radionuclide conjugates in oncology: a scoping review of first-in-human trials, dose escalation, imaging-guided selection, and dosimetry-guided dosing. Research Connections. 2026. doi:10.1093/rescon/vmag220
BibTeX
@article{Oisakede2026,
author = {Oisakede, Emmanuel O and Adegbenro, Ayobami T and Amhakhian, Oziegbe A and Ukponahunsi, Eddy and Olawade, David B},
title = {Clinical translation of antibody-radionuclide conjugates in oncology: a scoping review of first-in-human trials, dose escalation, imaging-guided selection, and dosimetry-guided dosing},
journal = {Research Connections},
year = {2026},
doi = {10.1093/rescon/vmag220}
}
EUVIMED